Psychedelic Spotlight
  • News
  • Culture
  • Business
    • Business
    • News
    • Editorial
    • Stock Reports
    • Videos
    • Interviews
  • Research
  • Policy
  • Media
    • Podcast
    • Videos
  • Work With us
    • Work With Us
    • Contact Us
    • About
  • Media Kit
  • Bonfire Community
    • Work with us
  • Search
  • Menu Menu
Home1 / Psychedelic Spotlight News2 / Business3 / Stock Reports4

Psychedelic Business Spotlight – May 13

byGreg GilmanonMay 13, 2022
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn

This week in psychedelic business news: Beckley Retreats sets launch; another shark swims into the psychedelics industry; and MindMed shares promising LSD study results.

Beckley Retreats to Launch in Jamaica This Fall

This week in psychedelic business news, Beckley Retreats, a psilocybin-focused, holistic wellbeing company, announced sessions will begin in Jamaica in October. The Caribbean country is one of the few where the cultivation, gifting, and consumption of psilocybin mushrooms is legal, so it's an ideal starting point for the comprehensive program, which includes curated pre-retreat preparation, as well as post-retreat integration to encourage the formation of new habits, practices, and thought patterns. CEO Neil Markey leads a team of clinical experts and spiritual guides. The retreat, which costs at least $5,500 per person, combines ancient teachings and mindful practices with individual guidance to create an unparalleled experience.

Field Trip and Nue Life Collaborate to Bring Psychedelic Therapy Home

Field Trip Health (NASDAQ: FTRP, TSX: FTRP) launched Field Trip at Home™ Powered by Nue Life this week, now providing ketamine treatments from the comfort of a person’s home, in addition to 12 psychedelic-assisted therapy clinics across North America and Europe. Through this arrangement with Nue Life — an advanced wellness platform for personalized, at-home psychedelic care — Field Trip now offers increased accessibility and convenience for those interested in pursuing ketamine therapy outside of a clinic setting through Nue Life’s telehealth offerings: an interactive companion app and virtual aftercare programs. “In late April we announced that Field Trip’s clinics and technology division is ready to evolve into its own independent, standalone company. As part of that spinout, our name is changing from Field Trip Health to Field Trip Health & Wellness, which is in recognition of our promise to expand access to more people who can benefit from these powerful therapies,” says Ronan Levy, Field Trip’s Executive Chairman. “Launching Field Trip at Home™ Powered by Nue Life is the first step in delivering on that promise.”

Related Posts

The Biggest Psychedelic News Stories of the Week – June 3

Trip Do's and Don'ts: What to Avoid During Your Psychedelic Experience

The Largest Phase 3 Trial on Psilocybin for Depression Has Kicked Off

Single Dose of Psilocybin Yields Long-Term Depression Remission in Over 50% of Cancer Patients

Ketamine Wellness Centers Offers Arizona Veterans Treatment at No Out-of-Pocket Cost

Ketamine Wellness Centers, the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Corp (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), has partnered with the Veterans Administration (VA) in Arizona to offer veterans suffering from treatment-resistant depression, PTSD and anxiety access to ketamine therapy at the KWC Arizona clinics in Phoenix, Tucson and Mesa–Gilbert at no out-of-pocket cost with prior authorization from the VA. Previously, the company's Burnsville, Minnesota location partnered with the VA to offer the same deal. “At KWC, we take great pride in supporting our veterans in Arizona and across the country. Unfortunately, veterans often face challenges securing the care they seek, such as access and affordability, and our partnership with the Veterans Administration will help to alleviate some of them,” says Kevin Nicholson, CEO of KWC and COO of Delic, said. “We anticipate even more VA contracts as a result of the resources KWC has committed to expanding insurance coverage for our patients.”

OG ‘Shark Tank' Star Kevin Harrington Invests in Psycheceutical

More sharks have entered the psychedelic business. Original Shark Tank entrepreneur Kevin Harrington has joined biopharmaceutical company Psycheceutical, Inc., a wholly owned subsidiary of Psycheceutical Bioscience, Inc. (OTC: BWVI),  as the corporation's newest investor and strategic advisor, providing expertise on the strategy, direction, and execution of the company's growth and development in pursuit of its mission to accelerate the research, availability, and delivery of psychedelic pharmaceutical medicines.  Harrington, who created the As Seen on TV brand, says, “It seems clear to me that psychedelics are the future of mental health treatment, but they need to be delivered safely like pharmaceutical medicines, which is why I'm so excited about Psycheceutical.”

MindMed LSD Trial for Anxiety Deemed a Success

Psychedelic business MindMed (Nasdaq: MNMD, NEO:MMED) finally gave the world a glimpse into its LSD-as-medicine project this past Wednesday while speaking at the highly anticipated PSYCH Symposium in London. Researchers Prof. Matthias Liechti and Dr. Friederike Holze presented positive topline data of a Phase 2, double-blind, placebo-controlled study, attempting to treat anxiety disorders with LSD in 46 patients. Patients received 200 µg (micrograms) of LSD, which is considered a large dose. The study found that 65% of patients saw their anxiety levels drop by at least 30% from where they were before treatment, 16 weeks after dosing. Read the full story here.

Have you heard about our new community?

We’re excited to announce Bonfire -
a personal growth community
for people who are interested in psychedelics.

Join us for our launch event on July 18th, where we’ll share about the work we’ll be doing together to actualize our personal missions, grow, and heal together.

Sign Up Here
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *

Related News

Why NeonMind Is Betting on Psilocybin to Curb the Global Obesity Epidemic

Why NeonMind Is Betting on Psilocybin to Curb the Global Obesity Epidemic

Business
The psychedelic bioscience company's top advisor tells Psychedelic Spotlight that psilocybin "affects at least the 5h2C receptor, which is dedicated towards appetite and appetite suppression."
0 Comments
/
September 28, 2021
Oregon's Psilocybin Services Policy with Sam Chapman

Interview with Sam Chapman, Executive Director of the Healing Advocacy Fund

Podcasts
This week on the Psychedelic Spotlight podcast, we talk with Sam Chapman. Sam is a resident of Portland, Oregon, he was the Campaign Manager for Oregon Measure 109, and is now the Executive Director of the Healing Advocacy Fund, a nonprofit organization dedicated to supporting the nation’s first regulated psilocybin therapy program.
0 Comments
/
May 12, 2022
DEA Right to Try Psilocybin

DEA Under Pressure from Terminally Ill “Right to Try” Psychedelic Advocates

Policy
The DEA is denying psilocybin therapy for dying patients despite the Right To Try Act. Here’s a timeline of the fight to access to psychedelic therapy for terminally ill patients 
1 Comment
/
August 12, 2022

Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.

Explore

  • About
  • Treatment
  • Work With Us
  • News
  • Privacy Policy
  • Terms and Conditions

Resources

  • Conferences
  • Experts
  • Glossary
  • Therapy

Subscribe

           

© 2022 Psychedelic Spotlight. | Owned and operated by PSYC Media Corporation, Inc. a US publicly traded company (OTCPink: PSYC) | All Rights Reserved.
Interview with Sam Chapman, Executive Director of the Healing Advocacy FundOregon's Psilocybin Services Policy with Sam ChapmanMindMed Releases LSD for Anxiety Data ! (MNMD, MMED)
Scroll to top

Get a roundup of Psychedelic news stories in your inbox

By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.

Hidden
Which list would you like to subscribe to?
Enter your email below to subscribe to Psychedelic News.